References
- Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–97.
- Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793.
- Child JA, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.
- Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.
- Mossad SB, Longworth DL, Goormastic M, et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 1996;18:265–271.
- Afessa BS, Peters G. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006;27:297–309.
- Hamalainen S, Kuittinen T, Matinlauri I, et al. Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome. Scand J Infect Dis. 2009;41:14–20.
- Wang XS, Shi Q, Shah ND, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014;20:1366–1374.
- Mathew S, Adel N, Rice RD, et al. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant. 2010;45:1522–1527.
- Felfly H, Trudel M. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions. Br J Haematol. 2010;148:646–658.
- Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol. 2007;25:51–69.
- Abdel-Razeq H, Pohlman B, Andresen S. A randomized study of multi-day infusion of autologous peripheral blood progenitor cells. Bone Marrow Transplant. 1998;21:221–223.
- Cleeland CS, Mendoza TR, Wang XS. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646.
- Mavroudis D, Read E, Cottler-Fox M, et al. CD34 + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223–3229.
- Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969.
- Shah N, Shi Q, Williams LA, et al. Higher stem cell dose infusion as rescue after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biology Blood Marrow Transplant. 2015. [Epub ahead of print]. DOI: 10.1016/j.bbmt.2015.07.036.
- Fortner BV, Houts AC. Greater physical and psychological symptom burden in patients with grade 3/4 chemotherapy-induced neutropenia. Support Cancer Ther. 2006;3:173–177.